Gefitinib companion diagnostic - AstraZeneca/QIAGEN

Drug Profile

Gefitinib companion diagnostic - AstraZeneca/QIAGEN

Alternative Names: Circulating tumour DNA test - AstraZeneca/QIAGEN; Liquid biopsy based gefitinib companion diagnostic - AstraZeneca/QIAGEN; therascreen EGFR RGQ PCR Kit (gefitinib)

Latest Information Update: 15 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator QIAGEN
  • Developer AstraZeneca; QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 14 Jul 2015 Launched for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
  • 13 Jul 2015 Launched for Non-small cell lung cancer (Diagnosis) in European Union (unspecified route)
  • 13 Jul 2015 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top